JAIDS Journal of Acquired Immune Deficiency Syndromes
32:576–579 © 2003 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 32, 2003

Author Index

Aarnoutse RE, 287
Aberg JA, 153
Abrams E, 192
Acosta EP, 506
Adu-Oppong A, 399
Adult/Adolescent Spectrum of HIV Disease Group, 499
Aga E, 281
Agbaria R, 477
Alarcón A, 240
Alix J, S39
Alkaer G, 112
Alves K, 551
Ananworanich J, 570
Anastos K, 298
Anderson DM, 469
Anderson RN, 62
Angarano G, 268
Antelman G, 560
Anthony JC, 429
APROCO Study Group, 38
Arakaki R, 281
Archibald CP, S24
Arduino RC, 399
Ariyoshi K, 157
Armon C, 48
Aronson N, 9
Arruda JS, 388
Arya J, 469
Asensi V, 348
Astemborski JA, 429
Aukrust P, 354
Ayuka F, 223

Bai J, 245
Bai Y, 406
Balzarini J, 477
Barak J, 477
Barcán LA, 104
Bardeguez AD, 170
Barroso PF, 435
Bartholomew C, 94
Bastos FI, 338
Bayer R, 182
Beccio S, 482
Beer BE, 362
Belloso WH, 104
Benning L, 298
Berchich L, 259
Berría MI, 441
Betha G, 345
Beyrer C, 311
Bhattacharya SK, 115
Biggar RJ, 527
Biglione MM, 441
Binson D, 417
Birch C, 57
Birkhead GS, 292
Birx DL, 9, 215
Blanche S, 112
Blattner WA, 94
Blaxhult A, 452
Blijenberg BG, 135
Blok WL, 135
Blumberg SJ, 77
Bomfim A, 435
Bonu S, 388
Bosch RJ, 281
Brahmbhatt H, 394
Brambilla P, 482
Branson BM, 318
Bressan C, 435
Bricalli D, 482
Brookmeyer R, 311
Brown T, S12
Bulterys M, 192
Burchell AN, 534
Burgard M, 112
Burger D, 375
Burger DM, 135, 287
Busch MP, 551

Cafarella T, 94
Callea F, 259
Calzavara LM, 534
Cao C, 406
Cao Y, 124
Cardiello PG, 375
Carosi G, 259, 268
Carpenter CCJ, 203
Carr A, 542
Carr JK, 215
Carrieri P, 38
Cartón JA, 348
Casado L, 348
Casari S, 259
Casau NC, 494
CASCADE Collaboration, 303
Caseiro M, 551
Castelli F, 259, 268
Castro E, 338
Catania JA, 417
Cazali N, 112
Celentano DD, 86, 229
Celum CL, 318
Chadapaud S, 462
Chapman V, 506
Cheku B, 292
Chen JL, 182
Chêne G, 38
Cheng J, 245
Chernoff M, 281
Chiesi A, 452
Chironi G, 490
Christophersen B, 354
Chuenyam T, 570
Cleghorn FR, 94
Clevenbergh P, 345
Clouse KA, 362
Cogny A, 490
Cohen CR, 223
Cohen MS, 131
Colby DJ, 80
Colebunders R, 452
Coletti AS, 161
Combadière C, 335
Connick E, 469
Constantine NT, 94
Contopoulos-Ioannidis DG, 70
Contos MJ, 30
Coombs R, 170
Coombs RW, 281
Cooper D, 57
Cooper DA, 375, 542
Cossarizza A, 370
Coutinho RA, 514
Critchlow CW, 318
Crowe S, 57
Cunningham B, 170

Dalessandro M, 464
Danoff A, 298
Das P, 115
de Groot R, 135
Debré P, 335

JAIDS Journal of Acquired Immune Deficiency Syndromes
32:576–579 © 2003 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 32, 2003

Author Index

Aarnoutse RE, 287
Aberg JA, 153
Abrams E, 192
Acosta EP, 506
Adu-Oppong A, 399
Adult/Adolescent Spectrum of HIV Disease Group, 499
Aga E, 281
Agbaria R, 477
Alarcón A, 240
Alix J, S39
Alkaer G, 112
Alves K, 551
Ananworanich J, 570
Anastos K, 298
Anderson DM, 469
Anderson RN, 62
Angarano G, 268
Antelman G, 560
Anthony JC, 429
APROCO Study Group, 38
Arakaki R, 281
Archibald CP, S24
Arduino RC, 399
Ariyoshi K, 157
Armon C, 48
Aronson N, 9
Arruda JS, 388
Arya J, 469
Asensi V, 348
Astemborski JA, 429
Aukrust P, 354
Ayuka F, 223

Bai J, 245
Bai Y, 406
Balzarini J, 477
Barak J, 477
Barcán LA, 104
Bardeguez AD, 170
Barroso PF, 435
Bartholomew C, 94
Bastos FI, 338
Bayer R, 182
Beccio S, 482
Beer BE, 362
Belloso WH, 104
Benning L, 298
Berchich L, 259
Berría MI, 441
Betha G, 345
Beyrer C, 311
Bhattacharya SK, 115
Biggar RJ, 527
Biglione MM, 441
Binson D, 417
Birch C, 57
Birkhead GS, 292
Birx DL, 9, 215
Blanche S, 112
Blattner WA, 94
Blaxhult A, 452
Blijenberg BG, 135
Blok WL, 135
Blumberg SJ, 77
Bomfim A, 435
Bonu S, 388
Bosch RJ, 281
Brahmbhatt H, 394
Brambilla P, 482
Branson BM, 318
Bressan C, 435
Bricalli D, 482
Brookmeyer R, 311
Brown T, S12
Bulterys M, 192
Burchell AN, 534
Burgard M, 112
Burger D, 375
Burger DM, 135, 287
Busch MP, 551

Cafarella T, 94
Callea F, 259
Calzavara LM, 534
Cao C, 406
Cao Y, 124
Cardiello PG, 375
Carosi G, 259, 268
Carpenter CCJ, 203
Carr A, 542
Carr JK, 215
Carrieri P, 38
Cartón JA, 348
Casado L, 348
Casari S, 259
Casau NC, 494
CASCADE Collaboration, 303
Caseiro M, 551
Castelli F, 259, 268
Castro E, 338
Catania JA, 417
Cazali N, 112
Celentano DD, 86, 229
Celum CL, 318
Chadapaud S, 462
Chapman V, 506
Cheku B, 292
Chen JL, 182
Chêne G, 38
Cheng J, 245
Chernoff M, 281
Chiesi A, 452
Chironi G, 490
Christophersen B, 354
Chuenyam T, 570
Cleghorn FR, 94
Clevenbergh P, 345
Clouse KA, 362
Cogny A, 490
Cohen CR, 223
Cohen MS, 131
Colby DJ, 80
Colebunders R, 452
Coletti AS, 161
Combadière C, 335
Connick E, 469
Constantine NT, 94
Contopoulos-Ioannidis DG, 70
Contos MJ, 30
Coombs R, 170
Coombs RW, 281
Cooper D, 57
Cooper DA, 375, 542
Cossarizza A, 370
Coutinho RA, 514
Critchlow CW, 318
Crowe S, 57
Cunningham B, 170

Dalessandro M, 464
Danoff A, 298
Das P, 115
de Groot R, 135
Debré P, 335

DeHovitz J, 210
Deibis L, 338
Delaney KM, 48
Di Iorio A, 464
Di Sora F, 424
Diaz RS, 551
Dickey WC, 77
Dieleman JP, 135
Dietrich M, 452
Dos Santos Moreira A, 338
Downs AM, S39
Droste JAH, 287
Duran S, 38
Dworkin MS, 499

Eboshida A, S55
Echeverría G, 338
Edwards J, 94
Eiraku N, 328
El Habib R, 9
Ellen JM, 388
Emery S, 57
Engels EA, 527
Ensoli F, 464
Erdem G, 370
Escaut L, 490
Escobar M, 534

Falasca K, 464
Falcao ME, 551
Fantry LE, 243
Faure S, 335
Favret M, 259
Fawzi WW, 560
Feldman JG, 210
Feldman MD, S1, S55
Feliu E, 347
Feng T, 131
Feng T-J, 124
Fleming PL, S68
Folkvord JM, 469
Fowler MG, 170
Fox L, 281
Foy H, S63
François C, 38
Frenkel LM, 170
Frøland SS, 354
Fuller CM, 86
Furukawa Y, 328

Galich AM, 104
Gallagher BK, 292
Galli C, 424
Galvin SR, 131
Gandia J, 170
García-Samaniego J, 465
Gardner LI, 203
Gariepy J, 490
Gazzard BG, 238
Geduld J, S24
Genin E, 335
Gerschenson M, 370
Geskus RB, 514
Gianotti N, 268
Gilleece YC, 238
Giordano TP, 399
Gisselquist D, 349
Glesby MJ, 494
Goedert JJ, 70, 527
Goldbaum GM, 318
Golden MR, 196
Goldenberg RL, 506
Goldwasser P, 210
Golub ET, 429
Gómez-Vera J, 240
González de Salmen B, 338
González-Lahoz J, 465
Goudsmit J, 514
Graviss EA, 399
Gray RH, 446
Greenblatt RM, 298
Grigolato P, 259
Grimes J, 9
Grimm TA, 362
Gross M, 161
Guimarães ML, 338
Gulick RM, 494
Gupta AK, 115
Gupta P, 435
Gyssens IC, 135

Hales G, 57
Hamers FF, S39
Hamouda O, S49
Handsfield HH, 196
Hanson DL, 499
Harrison LH, 435
Hashimoto S, S55
Hayes R, 351
Hazen R, 255
Heagerty P, 161
Heggelund L, 354
Hekster YA, 287
Henderson LA, 229
Hill A, 375
Hill C, 9
Hirsch VM, 362
Hirschel B, 542
Hittinger G, 462
HIV Outpatient Study Investigators, 48
Hoffman IF, 131
Hogg RS, 2, 522
Holman S, 210
Holmberg SD, 48, 203
Holmes KK, 196
Hong W-G, 124
Hoover DR, 429
Hopkins SG, 196
Hou J, 124
Hoy J, 57
Hu L-P, 124
Huang S, 170
Hugonnet S, 351
Hurley LB, 143

Ichikawa S, S55
Imam G, 394
Infuso A, S39
International Collaboration on HIV Optimism, 545
Ioannidis JPA, 70
Ivalo SA, 104
Izumo S, 328

Jack N, 94
Jacobson JM, 281
Jesudason MV, 573
Jin L, 124
Jiraphongsa C, S63
Johnson AM, 452
Johnson RP, 245
Jones JL, 499
Jones T, 170
Juethner SN, 153
Justman JE, 298

Kalayjian R, 281
Kaldor J, S18
Kamakura M, S1, S55
Kamemoto L, 370
Kannangai R, 573
Katlama C, 38, 452
Kelly RJ, 446
Kerr T, 2
Kihara M, S1, S55
Kim JH, 9
Kirk O, 452
Klein D, 143
Klein RS, 203
Koblin BA, 161
Kombila M, 345
Koopmans PP, 287
Kreisel K, 94
Kubota R, 328
Kumwenda-Phiri R, 506
Kurth A, 318

Labrique A, 311
Lacarelle B, 462
Ladisa N, 268
Lafeuillade A, 462
Lahart CJ, 399
Lang J-M, 38
Lange JM, 375
Lanier ER, 255
Latkin CA, 86
Law M, 57
Lazzari S, S3
Lazzarin A, 268
Lederman MM, 281
Lee F, 192
Lei Z-Y, 124
Leport C, 38
Levenson J, 490
Levine A, 298
Li K, 2

Lichtenstein KA, 48
Liu M-X, 124
Liu Z-D, 124
Lloyd RM Jr, 292
Lo Caputo S, 268
Lockhart D, 318
Loomis-Price LD, 9
López-Cortés LF, 240
Loughran TP, 406
Luketic VA, 30
Lungren JD, 452
Lutalo T, 446

Mahanontharit A, 375
Major C, 534
Mandalia S, 238
Manor E, 477
Manzoni P, 482
Maradona JA, 348
Marasco WA, 245
Mariner WK, 117
Maserati R, 268
Massi M, 424
Mata R, 240
Maupin R, 170
MaWhinney S, 469
Mazzotta F, 268
Mbulaiteye SM, 527
McDonald A, S18
McKenna MT, 62
McNaghten AD, 499
McNeil JG, 215
Meier AS, 223
Merrill D, 143
Metzger DS, 161
Meyer L, 335
Middleton T, 57
Miedema FA, 514
Millá F, 347
Mills AS, 30
Millson M, 534
Minkoff H, 210, 298
Moatti J-P, 38
Mofenson LM, 170
Mollnes TE, 354
Monhaphol T, 375
Monsuez J-J, 490
Montaner JSG, 522
Montella F, 424
Moore AL, 452
Moorman AC, 48
Mora S, 482
Morgado MG, 338
Morlese JF, 238
Morris M, 196
Msamanga G, 560
Muchina B, 223
Murakami A, 245
Mwachari C, 223
Myers L, 281
Myers T, 534

Nakagawa M, 328
Nakashima AK, S68
Narayan S, 572
Navarro J-T, 347
Nelson MR, 238
Nesheim S, 192
Ni A, 131
Nkoumou MO, 345
Nuesch R, 570
Núñez M, 465
Nyland SB, 406

O'Brien TR, 70
O'Shaughnessy MV, 2, 522
O'Sullivan MJ, 170
Odhiambo J, 223
Oleske JM, 353
Ompad DC, 86
Ono-Kihara M, S55
Oriol A, 347
Osame M, 328

Pachón J, 240
Paganelli R, 464
Palepu A, 522
Palumbo P, 192
Pandey K, 115
Parker MM, 292
Pathipvanich P, 157
Paul S, 494
Pellet P, 335
Peng L, 124
Penner J, 223
Pérez-Olmeda M, 465
Perman MI, 104
Perrin L, 542
Peterson KE, 560
Peyramond D, 38
Pezzotti P, 424
Phanuphak P, 375, 570
Phillips AN, 452
Phillips KA, 182
Pierotti P, 268
Piessens E, 298
Piliero P, 18
Pinti M, 370
Pisani E, S3
Pizarro M, 441
Pizzigallo E, 464
Poggi C, 462
Pollack LM, 417
Pons G, 112
Pozniak AL, 238
Prabu K, 573
Puca A, 441
Puoti M, 259
Purdue L, 281
Putzolu V, 259

Qazi NA, 238
Qiu Y, 124
Quartier P, 112

Quesenberry CP Jr, 143
Quirós RE, 104
Quiros-Roldan E, 259, 268

Rabidas VN, 115
Ramalingam S, 573
Ranjan A, 115, 572
Ratto-Kim S, 9
Rawal BD, 551
Razak MH, 311
Recchia O, 424
Reiss P, 514
Renzullo PO, 215
Rey E, 112
Rezza G, 424
Ribera J-M, 347
Rinehart AR, 268
Ríos P, 465
Ripamonti D, 259
Ristig MB, 153
Robison E, 298
Rodriguez-Guardado A, 348
Rojanawiwat A, 157
Rompalo AM, 203
Rosenberg HM, 62
Rosenberg PS, 70
Ross D, 351
Rossini A, 318
Rouzioux C, 112
Ruiz-Valderas R, 240
Rutherford G, 551
Ruxrungtham K, 375, 570

Saengwonloey O, S63
Sajja P, 399
Salomón HE, 441
Sanne I, 18
Sanyal AJ, 30
Sateren WB, 215
Sawanpanyalert P, 157
Schechter M, 435
Schechter MT, 2
Schiavone C, 464
Schlossberg J, 534
Schneider L, 482
Schnittman S, 18
Schock B, 281
Schuitemaker H, 514
Schuman P, 203
Schwartländer B, S3
Sciandra M, 424
Seage GR III, 161
Selik RM, 62
SEROCO Study Group, 335
Serwadda D, 446
Sewankambo NK, 446
Seyfried W, 153
Shafer KP, 551
Shapiro DE, 170
Sheon AR, 161
Shi M, 124
Shiffman ML, 30

Shikuma C, 370
Shikuma CM, 281
Shikuma KM, 370
Shiramizu B, 370
Siangphoe U, 570
Sill AM, 94
Simon A, 490
Sinha PK, 115
Sinicco A, 424
Sinkala M, 506
Small W, 2
Smith E, S33
Smith H, 94
Snyder S, 281
Solas C, 462
Soriano V, 465
Sperling RS, 170
Spiegelman D, 560
Spielberg F, 318
Spinetti A, 259
Spire B, 38
Spittal PM, 2
Spritzler J, 281
Squires K, 18
Srasuebkul P, 570
Sridharan G, 573
Stall RD, 417
Sterling RK, 30
Stern LD, 104
Stout JP, 506
Strathdee SA, 86, 229, 394, 429
Stravitz RT, 30
Stricker BCH, 135
Stringer JSA, 506
Sturkenboom MCJM, 135
Sucupira MC, 551
Sui J, 245
Suligoi B, 424
Sullivan K, 192
Sullivan T, 292
Sutherland D, S24
Sutherland J, S24
Swiss HIV Cohort Study, 542
Szczech LA, 203

Taylor J, 292
Tebas P, 153
Teeratakulpisarn S, 570
Telgt D, 135
Testolin C, 482
Thakur CP, 572
The European Collaborative Study, 380
Théodorou I, 335
Thiry A, 18
Tinelli C, 268
Todd J, 351
Tomasoni L, 259
Torti C, 259, 268
Travasi F, 464
Treluyer JM, 112
Tural C, 347
Tyndall M, 522
Tyndall MW, 2

Ueland T, 354
Ugen KE, 406
ul Hassan S, 394
Ungsedhaphand C, 570
Usuku K, 328

van Heeswijk RP, 375
van Rossum AMC, 135
Vanhems P, 542
Vanzulli A, 482
Veber F, 112
Vecchiet J, 464
Verma N, 115
Vermund SH, 506
Viciana P, 240
Viganò A, 482
Vijayakumar TS, 573
Villamor E, 560
Vink P, 192
Visnegarwala F, 399
Vittecoq D, 490
Vizzard J, 542
Vlahov D, 86, 229, 429
Vogel R, 388
Voirin N, 542

Wabwire-Mangen F, 446
Wade N, 292
Walker N, S3
Wallace E, 534
Wallis RS, 281
Wang B, 124
Wang F-S, 124
Wang Z, 124
Warachit P, 157
Ward DJ, 48
Ward MA, 388
Wawer MJ, 446
Weber K, 298
White AC Jr, 399
Williams C, 9
Williamson C, 153
Williamson JM, 203
Wilson MS, 30
Winkler C, 124
Wohlfeiler D, 417
Wongchoosie S, 157
Wood E, 2
Wood KC, 48
Wood RW, 318
Woods WJ, 417

Xu D-P, 124

Yamamoto T, S55
Yan P, S24
Yang G, 131
Ye J-J, 124
Yingseree P, 157
Yip B, 522
Yoshiike K, 157

Zafar T, 394
Zaltron S, 259
Zanini B, 259
Zhang B, 124
Zhang D, 245
Zietse R, 135
Zingariello P, 464
Zorrilla CD, 170

JAIDS Journal of Acquired Immune Deficiency Syndromes
32:580–589 © 2003 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 32, 2003

Subject Index

Abnormalities, in uninfected children exposed to antiretroviral therapy in utero or early life, 380
Acute retroviral syndrome, incubation and duration of symptoms of as independent predictors of AIDS progression, 542
Adherence
  to antiretroviral therapy and HIV RNA persistence in semen, 435
  to highly active antiretroviral therapy in urban clinic patients, 399
Adipose tissue, intra-abdominal, with increased exposure to highly active antiretroviral therapy in HIV-infected children, 482
Adolescents
  applying for military service, HIV-1 infection among, 215
  HIV-1 infection risk to in rural Uganda, 446
  social circumstances of injection drug use initiation in shooting galleries, 86
  trends in AIDS cases in, S68
Afghanistan, HIV knowledge and risk behaviors among drug users in, 394
Africa
  age differences in sexual partners and HIV-1 risk in, 446
  meningitis in HIV-positive versus -negative patients in (letter), 345
  risk factors for pneumonia among urban-dwelling HIV-infected women in, 223
  sexual transmission of HIV in (letter), 349, 351
Age, HIV-1 infection risk and in rural Uganda, 446
AIDS case reporting, S1
  in Australia, S18
  in Canada, S24
  in Denmark, S33
  in Europe, S39
  in Germany, S49
  in Japan, S55
  surveillance systems in, S3
  in Thailand, S63
  in United States, S68
AIDS cases, definition of, S68
AIDS epidemic
  gay bathhouses in, 417
  in India (letter), 573
AIDS incidence, trends in, S68
AIDS progression
  immune deficiency and risk for malignancy with, 527
  incubation and duration of symptoms at acute retroviral syndrome and, 542
  markers and cofactors in predicting, 514
  psychological distress and in injection drug users, 429
AIDS-related lymphoma, improved outcome of with virologic response to HAART (letter), 347
AIDS-related opportunistic infections, risk factors for among urban-dwelling HIV-infected women, 223
Alanine aminotransferase flares, in combination antiretroviral therapy, 259
Allele frequencies, in Chinese ethnic groups, 124
ALVAC-HIV (vCP205) immunization, env-specific T-cell epitopic responses with, 9
Amniocytes, phosphorylation of 3′-azidothymidine in, 477
Anti-HIV agents, impaired virologic response to with ongoing injection drug use, 522
Anti-HIV immunotherapy, macaque primary CD4-enriched peripheral blood mononuclear cell activation in, 245
Antibody avidity, in identifying recent HIV infections, 424
Antiretroviral drugs
  measurement of by interlaboratory quality control program, 287
  survival benefit from in resource-constrained setting, 157
Antiretroviral-naive population, nonnucleoside reverse transcriptase inhibitor resistance among, 153
Antiretroviral therapy
  adherence to and HIV RNA persistence in semen, 435
  carotid intima-media thickness and, 490
  cessation of prophylactic use of in reducing vertical transmission, 170
  combination, efficacy and treatment-limiting toxicity of in treatment-experience patients, 494
  differences in prescription of in HIV-infected patients, 499
  in utero or early life exposure to, 380
  limited evolution of resistance-associated mutations of, 57
  lipoatrophy incidence and risk factors with, 48
  pharmacokinetics and efficacy of saquinavir-sgc, low-dose ritonavir and efavirenz after (letter), 240
  severe hepatotoxicity of, 259
  strategies perinatal HIV transmission prevention with in high-prevalence, resource-poor settings, 506
  variables in lipodystrophy response to, 104
  viral load and in children (letter), 112
Antiretroviral therapy-naive seroconverters, short-term CD4 cell response after HAART initiation in, 303
Apoptosis, prednisone effects on, 281
Appointment adherence, use of highly active antiretroviral therapy and, 399
Argentina, cluster of human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in, 441

Asia
HIV/AIDS surveillance in, S63
HIV knowledge and risk factors among men who have sex with men in, 80
pharmacokinetics of saquinavir with ritonavir in HIV-1-infected subjects in, 375
survival benefit from non-highly active antiretroviral therapy in, 157
At-risk populations
defining, S3
informed consent process for in HIV vaccine efficacy trials, 161
Atazanavir, phase 2 clinical trial of with didanosine and stavudine, 18
Attitudes, in voluntary HIV testing among inmates, 534
Australia, HIV/AIDS surveillance systems in, S18
Automated enzyme immunoassay, in identifying recent HIV infections, 424
Avidity index, in identifying recent HIV infections, 424
AxSYM, in identifying recent HIV infections, 424
Azidothymidine, phosphorylation of in maternal and fetal peripheral blood mononuclear cells during gestation and at term, 477

B/F recombinant virus, in Venezuela, 338
Bacterial meningitis, in HIV-positive versus -negative patients (letter), 345
Baseline model, for predicting residual time to AIDS and death, 514
Bathhouses, public policy regulating, 417
Behavior change, CDC guidelines for, 182
Behavioral methodologies, versus behavioral surveillance, S12
Behavioral risk, in voluntary HIV testing among inmates, 534
Behavioral surveillance, S1
in Australia, S18
in Canada, S24
in catalyzing action, S12
in Denmark, S33
in Germany, S49
in Japan, S55
in Thailand, S63
in United States, S68
Behavioral surveys, repeated, S3
Biological surveillance data, in evaluating response, S3
Blood donors
HIV surveillance among in Europe, S39
HTLV-I-related clinical and laboratory findings in, 328
Blood HIV-1 RNA levels, with resistance to lopinavir (letter), 462
Burma, assessing magnitude of HIV/AIDS epidemic in, 311

C-reactive protein
in HIV disease progression, 354
as mortality predictor in HIV-1-infected women, 210
Canada
combining data sources in monitoring HIV epidemic in, S24
voluntary HIV testing among inmates in, 534
Cancer, immune deficiency and risk for among AIDS patients, 527
Carotid arteries, thickness of in heavily pretreated HIV-infected patients, 490
Case surveillance
in Australia, S18
in Canada, S24
in Denmark, S33
in Europe, S39
in Germany, S49
in Japan, S55
in United States, S68
CCR2 allele frequencies, in Chinese populations, 124
CCR5 allele frequencies, in Chinese populations, 124
CCR5-Δ32 heterozygosity, in risk of perinatal HIV-1 infection, 70
CCR5 gene
32-base pair deletion distribution of in Chinese minorities, 131
expression of in Chinese minorities, 131
CD4 cells
count of
gender and in response to highly active antiretroviral therapy, 452
and risk for malignancy among AIDS patients, 527
counts of
prednisone effects on, 281
optimization of ex vivo activation and expansion of, 245
short-term response of after HAART initiated from seroconversion, 303
$CD8^+$ cells, HIV-1-producing cells and in human lymphoid tissue, 469
Cell-mediated immunity, with undetectable viral load on protease inhibitor- versus non-protease inhibitor-based highly active antiretroviral therapy (letter), 570
Cell proliferation, of macaque primary CD4-enriched peripheral blood mononuclear cell, 245
Centers for Disease Control, HIV counseling and testing guidelines of, 182
Chemokines, in HIV-1 disease progression, 335
Children
AIDS trends in, S68
antiretroviral drug plasma concentrations and viral load in (letter), 112
exposed to antiretroviral therapy in utero or in early life, 380
increased lipodystrophy with exposure to highly active antiretroviral therapy in, 482
zidovudine prophylaxis for AIDS in, 170
Chimpanzees, zoonotic cross-species transmission of SIVs from, 362
China, CCR5 gene 32-base pair deletion and CCR5 expression in minorities in, 131
Chinese populations
CCR5 gene 32-base pair deletion and CCR5 expression in, 131
surveys of allele frequencies in, 124
Clinical progression, gender and in highly active antiretroviral therapy, 452
Clinical trials
phase 2, of atazanavir with didanosine and stavudine, 18
of prednisone, 281

Cofactors, in predicting residual time to AIDS and death, 514
Coinfection
clinical spectrum of hepatitis C virus in, 30
of kala-azar in India (letter), 572
modulation of HIV infection and type 1 cytokine expression in, 406
of visceral leishmaniasis (letter), 115
Combination drug therapy
efficacy and treatment-limiting toxicity of in treatment-experienced patients, 494
severe hepatotoxicity of, 259
Community, safer injection facilities impact on, 2
Complement, in HIV disease progression, 354
Consistency analysis, of variables in lipodystrophy syndrome, 104
Cord blood mitochondrial DNA toxicity, in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy, 370
Coreceptors
in Chinese populations, 124
macaque primary CD4-enriched peripheral blood mononuclear cell, 245
Corticosteroids, in T-cell loss in AIDS, 281
Counseling preferences, overcoming barriers to, 318
Creatinine serum levels, in mortality in HIV-infected women, 203
CREST study, on antiretroviral therapy resistance-associated mutations, 57
Cross-species transmission, multiple lineages of SIVs in, 362
CX3CR1 genotypes, deleterious genetic influence of on HIV-1 disease progression, 335
Cytokines, type 1, modulation of expression parameters of by morphine during in vitro HTLV-I and HIV-1 coinfection, 406
Cytotoxic T lymphocytes, HIV-1-producing in human lymphoid tissue, 469

Data sources, in HIV epidemic monitoring in Canada, S24
Death, causes of, changing rules for selecting, 62
Death certificates, changing rules for underlying causes in, 62
Demographic variables, in HIV-1 infection prevalence among military service applicants, 215
Denmark, HIV/AIDS surveillance in, S33
Developed countries, AIDS surveillance in, S1
Developing countries
AIDS surveillance in, S1
survival benefit from non-highly active antiretroviral therapy in, 157
Diabetes mellitus
protease inhibitor-associated (editorial), 243
protease inhibitor use and among HIV-infected women, 298
Diagnosis
medical encounters before, 143
quantitative RNA testing of infants in, 192
Diagnostic tests, in identifying recent HIV infections, 424
Didanosine, with atazanavir, phase 2 clinical trial with, 18
Disease progression
deleterious genetic influence of CX3CR1 genotypes on, 335
gender and in highly active antiretroviral therapy, 452
incubation and duration of symptoms at acute retroviral syndrome and, 542
mannose-binding lectin and, 354
markers and cofactors in predicting, 514
psychological distress and in injection drug users, 429
zidovudine prophylaxis to prevent, effect of cessation of during pregnancy, 170
Drug interactions, of saquinavir with ritonavir in HIV-1-infected subjects, 375
Drug resistance
among antiretroviral-naive HIV-positive pregnant women, 153
HIV-1 RNA levels and in semen versus blood with lopinavir-containing regimen (letter), 462
limited evolution of mutations in testing for, 57
prevalence of among HIV-infected newborns, 292
with real versus virtual phenotype, 268
Drug use, factors in readiness to stop, 229
Dual energy x-ray absorptiometry (DEXA), in analysis of lipodystrophy syndrome, 104
Dual therapy, survival benefit from in resource-constrained setting, 157
Dyslipidemia, with atazanavir with didanosine and stavudine, 18

Early detection
medical encounters before HIV-1 diagnosis in, 143
strategies for HIV testing in, 318
Eastern Europe, HIV/AIDS surveillance in, S39
Editorials
JAIDS at 15: meeting the challenge, 1
Long-term outcomes in infants born to HIV-infected women, 353
Protease inhibitor-associated diabetes mellitus: a potential cause of morbidity and mortality, 243
Taking informed consent seriously in global HIV vaccine research, 117
Efavirenz, pharmacokinetics and efficacy of in patients with prior antiretroviral therapy (letter), 240
Efficacy
of atazanavir with didanosine and stavudine, 18
cell type and, 255
of lopinavir in individuals experiencing protease inhibitor failure (letter), 238
of saquinavir-sgc, low-dose ritonavir and efavirenz after antiretroviral therapy (letter), 240
Emtricitabine, cell type and anti-HIV-1 efficacy of, 255
Endocrine function, with protease inhibitor use in HIV-infected women, 298
Env-specific T-cell epitopic responses, in HIV-1-infected and -uninfected adults, 9
Epidemic monitoring
combining data sources in, S24
in Japan, S55
Epidemic trends
interpreting data in, S3
monitoring of, S1
Epidemics
assessing magnitude of in Burma, 311
concentrated, S3

generalized, S3
surveillance systems for, S3
Epidemiology
of AIDS in Germany, S49
of CCR5 gene 32-base pair deletion and CCR5 expression in Chinese minorities, 131
of clients mobile health vans and traditional STD clinics, 388
of HIV-1 infection
among U.S. military personnel, 215
in Venezuela, 338
of immune deficiency and risk for malignancy in AIDS, 527
of progression to AIDS in injection drug users, 429
of protease inhibitor use and diabetes mellitus in HIV-infected women, 298
proteinuria and elevated serum creatinine levels in, 203
of risk behaviors in mentally ill, 77
Erratum: "Current situation and regional perspective on HIV/AIDS surveillance in Europe" Hamers et al. (2003;32(suppl 1):S39-S48), 467
Ethics
of informed consent in AIDS vaccine research (editorial), 117
in new CDC guidelines for HIV counseling and testing, 182
Ethnic groups
CCR5 gene 32-base pair deletion and CCR5 expression in, 131
surveys of allele frequencies in, 124
use of highly active antiretroviral therapy among, 399
Europe
AID surveillance in, S1
current situation and regional perspectives on HIV/AIDS surveillance in, S39
uninfected children exposed to antiretroviral therapy in utero or early life in, 380

Fat loss, abnormal, incidence and risk factors for in ambulatory HIV-1-infected patients, 48
Fetal peripheral blood mononuclear cells, phosphorylation of 3′-azidothymidine in during gestation and at term, 477

Gabon, meningitis in HIV-positive versus -negative patients in (letter), 345
Gay bathhouses, public policy regulating, 417
Gay men
HIV knowledge and risk factors among in Vietnam, 80
HIV treatments optimism among, 545
new strategies among clients of sex venues for, 318
public policy regulating risk behaviors of in bathhouses, 417
Gelatin capsules, hard and soft, pharmacokinetics of, 375
Gender, virologic, immunologic, and clinical response to highly active antiretroviral therapy and, 452
Gene therapy strategies, macaque primary CD4-enriched peripheral blood mononuclear cell activation in, 245
Genetics, in HIV-1 disease progression, 335
Genotipo-Fenotipo di Resistenza (GenPheRex) trial, follow-up of, 268
Genotype
of Chinese minorities, 131
in nonnucleoside reverse transcriptase inhibitor resistance among HIV-positive pregnant women, 153
Genotypic resistance
prevalence of among HIV-infected newborns, 292
to zidovudine prophylaxis to reduce vertical transmission, 170
Geographic diversity, of HIV-1 infection prevalence among military service applicants, 215
Germany, HIV/AIDS surveillance in, S49
Gestation, phosphorylation of 3′-azidothymidine in maternal and fetal PBMCs during, 477

Harm reduction, safer injection facilities in, 2
HDL cholesterol, increased intra-media thickness and, 490
Health department contact, in partner notification, 196
Health-related quality of life, after highly active antiretroviral therapy, 38
Health surveys, of prevalence of HIV risk behaviors, risk perceptions, and testing among mentally ill, 77
Hepatitis C virus
clinical spectrum of in HIV coinfection, 30
genotypes of in treatment failure for hepatitis C virus in HIV-positive drug users (letter), 465
with HIV infection and lipodystrophy (letter), 348
treatment failure for in HIV-positive drug users (letter), 465
Hepatotoxicity, of combination antiretroviral treatment, 259
Heroin users, HIV knowledge and risk behaviors among in Afghanistan and Pakistan, 394
Heteroduplex mobility assay, of HIV-1 subtypes in Venezuela, 338
High-prevalence, resource-poor setting, strategies for administering nevirapine to prevent perinatal HIV transmission in, 506
High-risk behavior
accessing populations with, S3
informed consent process for in HIV vaccine efficacy trials, 161
Highly active antiretroviral therapy
effectiveness of, S39
factors associated with in new urban clinic patients, 399
gender and virologic, immunologic, and clinical response to, 452
health-related quality of life after, 38
increased lipodystrophy with exposure to in HIV-infected children, 482
lipoatrophy incidence and risk factors with, 48
lipodystrophy syndrome with, 104
mannose-binding lectin in disease progression and, 354
phase 2 clinical trials of in antiretroviral-naive subjects, 18
prescription differences for in large cohort of HIV-infected patients, 499
protease inhibitor-based versus non-protease inhibitor based (letter), 570
real versus virtual phenotype guiding, 268
short-term CD4 cell response after, 303
virologic response to

impaired with ongoing injection drug use, 522
improved outcome of AIDS-related lymphoma with (letter), 347
Histology, with combination antiretroviral therapy, 259
HIV-1 infection
among U.S. military service applicants, 215
C-reactive protein as mortality predictor in, 210
env-specific T-cell epitopic responses to ALVAC-HIV (vCP205) immunization in, 9
modulation of by morphine during in vitro HTLV-I and HIV-1 coinfection, 406
perinatal, *CCR5-Δ32* heterozygosity in risk of, 70
RNA levels of, resistance and drug diffusion with in semen versus blood during lopinavir regimen (letter), 462
two-stage sensitive/less-sensitive test strategy in classification of, 94
HIV-1-producing cells, $CD8^+$ cells and in human lymphoid tissue, 469
HIV-1 risk groups, allele frequencies in among Chinese, 124
HIV-2 sub-epidemic, in tertiary care center in south India (letter), 573
HIV-1 subtypes, in Venezuela, 338
HIV-1-uninfected adults, env-specific T-cell epitopic responses in, 9
HIV/AIDS epidemic, assessing magnitude of in Burma, 311
HIV/AIDS programs
effectiveness of, S49
monitoring effectiveness of, S55
in Thailand, S63
HIV/AIDS research, challenge of (editorial), 1
HIV/AIDS surveillance
in Australia, S18
challenges of, S3
in Denmark, S33
design and implementation of, S12
in Europe, S39
in Germany, S49
global perspective on, S3
in Japan, S55
in new era, S1
purposes of, S3
second generation, S3
in Thailand, S63
in United States, S68
HIV case reporting
in Canada, S24
in Denmark, S33
in Europe, S39
in Germany, S49
in Japan, S55
partner notification in, 196
in United States, S68
HIV coinfection
clinical spectrum of hepatitis C virus in, 30
of visceral leishmaniasis (letter), 115
HIV counseling, testing, referral (CTR) services
new CDC guidelines on, 182
in traditional STD clinics versus mobile health vans, 388
HIV drug resistance, with real versus virtual phenotype, 268
HIV infection
among adolescent and young adult injection drug users, 86
among pregnant women from Tanzania, 560
hepatitis C virus and lipodystrophy with (letter), 348
increased mortality rate from, 62
HIV knowledge, risk factors and among men who have sex with men in Vietnam, 80
HIV optimism, among gay men, 545
HIV risk, age differences in sexual partners and in rural Uganda, 446
HIV serosurveillance, in Europe, S39
HIV testing
anonymous clients in Santos, Brazil, 551
HIV risk behaviors and risk perceptions and in mentally ill, 77
new CDC guidelines on, 182
overcoming barriers to, 318
patterns of, S39
in surveillance systems in Australia, S18
voluntary, among inmates, 534
HIV vaccine
informed consent in research on (editorial), 117
prototype informed consent process for efficacy trials of, 161
Homosexual men. *See* Gay men
Human T-cell leukemia virus type I, modulation of during in vitro coinfection with HIV-1, 406
Human T-cell lymphotropic virus type I (HTLV-I)
clinical and laboratory findings for blood donors with, 328
myelopathy/tropical spastic paraparesis associated with, cluster of in Argentina, 441
preclinical symptoms of, 328
subgroups of, 328

Immune deficiency, among AIDS patients, 527
Immune reconstitution, with combination antiretroviral therapy, 259
Immune response
after HAART in seroconverters, 303
with undetectable viral load on protease inhibitor- versus non-protease inhibitor-based highly active antiretroviral therapy (letter), 570
Immunoassays, in identifying recent HIV infections, 424
Immunology
gender and in response to highly active antiretroviral therapy, 452
of prednisone with CD4 cell counts of 200–700 mm, 281
Immunotherapy, macaque primary CD4-enriched peripheral blood mononuclear cell activation in, 245
Incidence
avidity index and automated enzyme immunoassay in determining, 424
in Denmark, S33
India
HIV-2 sub-epidemic in (letter), 573
kala-azar coinfection with HIV in (letter), 572
visceral leishmaniasis and HIV coinfection in (letter), 115
Indinavir, persistent leukocyturia and loss of renal function with, 135
Infants
of HIV-infected women, long-term outcomes in (editorial), 353
quantitative RNA testing in HIV diagnosis of, 192

Information dissemination, AIDS surveillance data, S68
behavioral surveillance and strategies for, S12
in Canada, S24
in Europe, S39
Informed consent
in global HIV vaccine research (editorial), 117
for HIV vaccine efficacy trials, 161
in new CDC guidelines for HIV counseling and testing, 182
Injection drug users
HIV knowledge and risk behaviors among in Afghanistan and Pakistan, 394
HIV surveillance among
in Canada, S24
in Europe, S39
impaired virologic response to highly active antiretroviral therapy in, 522
needle exchange programs and readiness for cessation of drug use among, 229
partner notification services for, 196
psychological distress and progression to AIDS in, 429
safer injection facilities for, 2
social circumstances of in shooting galleries, 86
treatment failure for hepatitis C virus in (letter), 465
use of highly active antiretroviral therapy among, 399
Interferon, hepatotoxicity of, 259
Interferon-γ, morphine in modulating expression of with in vitro coinfection, 406
Interlaboratory quality control program, of antiretroviral drug measurements, 287
Interleukin-2, morphine in modulating expression of with in vitro coinfection, 406
International Classification of Diseases (CD), cause of death classified by, 62
International comparison, on HIV optimism among gay men, 545
Interventions
among adolescent and young adult injection drug users, 86
evaluating effectiveness of, S24
Intra-media thickness, antiretroviral therapy and, 490
In vitro coinfection, modulation of HIV infection and type 1 cytokine expression in, 406

Japan, HIV/AIDS surveillance in, S55

Kala-azar, and HIV coinfection in India (letter), 572
Kaposi sarcoma, immune deficiency and risk for among AIDS patients, 527
Kappa analysis, of variables in lipodystrophy syndrome, 104
Kenya, risk factors for pneumonia among urban-dwelling HIV-infected women in, 223
Knowledge, risk behaviors and among Pakistani and Afghani drug users, 394

Lamivudine, cell type and anti-HIV-1 efficacy of, 255
Late testing, medical encounters before HIV-1 diagnosis and, 143
Latin America
cluster of HTLV-I-associated myelopathy/tropical spastic paraparesis in, 441
HIV-1 subtypes in, 338
Lectin, mannose-binding, in HIV progression, 354
Leishmaniasis
HIV coinfection with in India (letter), 572
visceral, HIV coinfection with in India (letter), 115
Letters to editor
Bacterial and mycobacterial meningitis in HIV-positive compared with HIV-negative patients in an internal medicine ward in Libreville, Gabon, 345
The efficacy of lopinavir in individuals experiencing protease inhibitor failure, 238
Hepatitis C virus in patients with HIV infection and lipodystrophy, 348
HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen, 462
HIV-2 sub-epidemic not gathering speed: experience from a tertiary care center in South India, 573
Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy, 347
Increased production of oncostatin-M by lymphomononuclear cells from HIV-1-infected patients with neuroAIDS, 464
Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes?, 465
Kala-azar (visceral leishmaniasis) and HIV coinfection in Bihar, India: Is this combination increasing?, 572
Once-daily saquinavir-sgc plus low-dose ritonavir in combination with efavirenz, 240
Relationship between antiretroviral drug plasma concentrations and viral load in children, 112
Unanswered questions about sexual transmission of HIV in Mwanza, Tanzania, 349
Unanswered questions about sexual transmission of HIV in Mwanza, Tanzania: Authors' reply, 351
Visceral leishmaniasis and HIV coinfection in Bihar, India, 115
In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy, 570
Leukocyturia, persistent, loss of renal function in with indinavir treatment, 135
Lipoatrophy, incidence and risk factors for in ambulatory HIV-1-infected patients, 48
Lipodystrophy
agreement analysis of variables involved in, 104
with hepatitis C virus and HIV infection (letter), 348
incidence and risk factors for in ambulatory HIV-1-infected patients, 48
with increased exposure to highly active antiretroviral therapy in HIV-infected children, 482
with protease inhibitor use in HIV-infected women, 298
Liver
damage to with combination antiretroviral therapy, 259
disease of with hepatitis C virus and HIV coinfection, 30
histology of with hepatitis C virus in HIV coinfection, 30
Logistic regression models, for impaired virologic response to highly active antiretroviral therapy with ongoing injection drug use, 522

Lopinavir
efficacy of in individuals experiencing protease inhibitor failure (letter), 238
HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood with (letter), 462
with ritonavir, efficacy and treatment-limiting toxicity of with third protease inhibitor in treatment-experienced patients, 494
Lymph nodes, HIV-1-producing cells and $CD8^+$ cells in, 469
Lymphoid tissue, HIV-1-producing cells and $CD8^+$ cells in, 469
Lymphoma
AIDS-related, improved outcome of with virologic response to HAART (letter), 347
non-Hodgkin, immune deficiency and risk for among AIDS patients, 527
Lymphomononuclear cells, increased production of oncostatin-M by with neuroAIDS (letter), 464

Macaque primary CD4-enriched peripheral blood mononuclear cells, optimization of ex vivo activation and expansion of, 245
Macrophages, SIVs from multiple lineages infecting, 362
Malignancy, risk for among AIDS patients, 527
Mannose-binding lectin, in HIV disease progression, 354
Marital status, in risk of pneumonia among urban-dwelling HIV-infected women, 223
Markers, in predicting residual time to AIDS and death, 514
Mass screening, for military service applicants, 215
Maternal-fetal HIV transmission, phosphorylation of 3′-azidothymidine and, 477
Maternal HIV disease, zidovudine prophylaxis for, effect of cessation of, 170
Medical encounters, before HIV-1 diagnosis, 143
Meningitis, in HIV-positive versus -negative patients (letter), 345
Mentally ill, prevalence of HIV risk behaviors, risk perceptions, and testing among, 77
Meta-analysis, of *CCR5-Δ32* heterozygosity in risk of perinatal HIV-1 infection, 70
Microanatomy, of $CD8^+$ and HIV-1-producing cells in human lymphoid tissue, 469
Migration, in HIV epidemiology, S39
Military personnel, HIV-1 infection among, 215
Minority groups, CCR5 gene 32-base pair deletion and CCR5 expression in, 131
Mitochondrial DNA toxicity, in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy, 370
Mobile van clinic, versus traditional sexually transmitted disease clinic, 388
Molecular epidemiology, of HIV-1 in Venezuela, 338
Morbidity, protease inhibitor-associated diabetes mellitus in (editorial), 243
Morphine, in modulating in vitro HIV-1 and HTLV-I infection and type 1 cytokine expression, 406
Mortality
C-reactive protein as predictors of, 210
increase in due to changes in rules for selecting underlying cause of death, 62
with non-highly active antiretroviral therapy in resource-constrained setting, 157
protease inhibitor-associated diabetes mellitus in (editorial), 243
proteinuria and elevated serum creatinine levels in, 203
MSM. *See* Gay men
MT-4 cells, in anti-HIV-1 efficacy of lamivudine and emtricitabine, 255
Mutation, antiretroviral therapy resistance-associated, 57
Mycobacterial meningitis, in HIV-positive versus -negative patients (letter), 345
Myelopathy, HTLV-I-associated, cluster of in Argentina, 441

Naive patients, use of highly active antiretroviral therapy in, 399
Natural history, of protease inhibitor use and diabetes mellitus in HIV-infected women, 298
Needle exchange programs
new strategies among clients of, 318
in readiness for cessation of drug use, 229
Nelfinavir, versus atazanavir, 18
Nephropathy, HIV-associated, proteinuria and elevated serum creatinine levels in, 203
NeuroAIDS, increased production of oncostatin-M by lymphomononuclear cells with (letter), 464
Nevirapine, strategies for administering to prevent perinatal HIV transmission in high-prevalence, resource-poor settings, 506
Newborns, prevalence of genotypic drug resistance in, 292
Nonnucleoside reverse transcriptase inhibitors
quality control programs for, 287
resistance to among antiretroviral-naive HIV-positive pregnant women, 153
Nucleoside reverse transcriptase inhibitors, placenta and cord blood mitochondrial DNA toxicity in women receiving during pregnancy, 370

Oncostatin-M, increased production of by lymphomononuclear cells with neuroAIDS (letter), 464
Opportunistic infections, risk factors for among urban-dwelling HIV-infected women, 223
Outcome
assessment of with hepatotoxicity of combination antiretroviral therapy, 259
long-term, in infants born to HIV-infected women (editorial), 353

PACTG 076 protocol, maternal HIV disease progression and survival in, 170
Pakistan, HIV knowledge and risk behaviors among drug users in, 394
Partner notification, health department contact support for, 196
Pathogenesis
incubation and duration of symptoms at acute retroviral syndrome and, 542
prednisone effects on, 281
Pediatric AIDS
trends in, S68
zidovudine prophylaxis to prevent, 170
Perinatal counseling, new CDC guidelines on, 182

Perinatal genotypic drug resistance, prevalence of, 292
Perinatal HIV-1 infection, *CCR5-Δ32* heterozygosity in risk of, 70
Perinatal HIV transmission
  effects of cessation of zidovudine prophylaxis to reduce, 170
  strategies for administering nevirapine to prevent in high-prevalence, resource-poor settings, 506
Peripheral blood mononuclear cells
  macaque primary CD4-enriched, optimization of ex vivo activation and expansion of, 245
  phosphorylation of 3′-azidothymidine in, 477
Pharmacokinetics
  with indinavir treatment, 135
  of saquinavir-sgc, low-dose ritonavir and efavirenz after antiretroviral therapy (letter), 240
  of saquinavir with ritonavir in HIV-1-infected subjects, 375
Phenotype
  in nonnucleoside reverse transcriptase inhibitor resistance among HIV-positive pregnant women, 153
  real versus virtual in treatment of heavily pretreated patients, 268
Phosphorylation, of 3′-azidothymidine in maternal and fetal peripheral blood mononuclear cells during gestation and at term, 477
Placenta, mitochondrial toxicity and in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy, 370
Pneumonia, risk factors for in urban-dwelling HIV-infected women, 223
Polymorphism, in HIV-1 disease progression, 335
Population-based surveys
  of allele frequencies in Chinese ethnic groups, 124
  of prevalence of HIV risk behaviors, risk perceptions, and testing among mentally ill, 77
Poverty, in risk of pneumonia among urban-dwelling HIV-infected women, 223
Predictors, of AIDS progression, 542
Prednisone, immunology, virology, and safety of in HIV-1-infected subjects with CD4 cell counts of 200–700 mm, 281
Pregnancy
  effects of cessation of zidovudine prophylaxis during, 170
  HIV surveillance during in Europe, S39
  HIV testing during, S3
  new CDC guidelines on HIV counseling and testing during, 182
  nonnucleoside reverse transcriptase inhibitor resistance during, 153
  placenta and cord blood mitochondrial DNA toxicity during, 370
Prescription differences, in large cohort of HIV-infected patients, 499
Prevalence
  in Denmark, S33
  in Europe, S39
  in Thailand, S63
Prevention
  needle exchange programs and, 229
  new CDC counseling guidelines for, 182
  overcoming barriers to, 318
  safer injection facilities in, 2
Primate model, for cross-species transmission of simian immunodeficiency virus, 362
Prisoners, voluntary HIV testing among, 534
Prognosis
  early detection and, 143
  incubation and duration of symptoms at acute retroviral syndrome and, 542
  markers and cofactors in predicting for AIDS, 514
Protease inhibitors
  cell-mediated immunity with (letter), 570
  diabetes mellitus associated with (editorial), 243
  in HIV-infected women, 298
  efficacy and treatment-limiting toxicity of in treatment-experienced patients, 494
  efficacy of lopinavir in individuals experiencing failure of (letter), 238
  evolution in, 57
  pharmacokinetics of in HIV-1-infected subjects, 375
  phase 2 clinical trials with, 18
  quality control programs for, 287
Proteinuria, in mortality in HIV-infected women, 203
Psychological distress, AIDS progression and in injection drug users, 429
Psychosocial factors, in progression to AIDS in injection drug users, 429
Public health
  AIDS surveillance data in, S68
  partner notification services in, 196
  safer injection facilities impact on, 2
Public policy, regulating private and public space in gay bathhouses, 417
Puna Jujeña natives, cluster of HTLV-I-associated myelopathy/tropical spastic paraparesis in, 441

Quality control
  of antiretroviral drugs, 287
  in HIV/AIDS surveillance, S1
Quality of life, health-related, after highly active antiretroviral therapy, 38
Quantitative RNA testing, for HIV diagnosis of infants, 192

Race, HIV-1 infection and among military service applicants, 215
Randomized trial, of prototype informed consent process for HIV vaccine efficacy, 161
Renal function
  HIV-associated abnormalities in, 203
  loss of with persistent leukocyturia in indinavir treatment, 135
Research
  challenge of (editorial), 1
  informed consent in (editorial), 117
Resistance
  mutations associated with, limited evolution of, 57
  prevalence of among HIV-infected newborns, 292
  testing of, real versus virtual phenotype in, 268
Reverse transcriptase, limited evolution of resistance-associated mutations with, 57

Reverse transcriptase inhibitors, diabetes mellitus and in HIV-infected women, 298
rgp160MN/LAI-2, with ALVAC-HIV (vCP205) immunization, 9
Risk assessment, medical encounters before HIV-1 diagnosis in, 143
Risk behaviors
changing, S12
in epidemics, S3
in HIV-1 infection prevalence among military service applicants, 215
HIV knowledge and among Pakistani and Afghani drug users, 394
in HIV transmission in Japan, S55
needle exchange programs and readiness to stop, 229
prevalence of and testing among mentally ill, 77
sexually transmitted infections and, S39
in voluntary HIV testing among inmates, 534
Risk factors
among men who have sex with men in Vietnam, 80
for HIV infection among adults with mental disorders, 77
for increased carotid artery thickness in heavily pretreated HIV-infected patients, 490
for lipoatrophy in ambulatory HIV-1-infected patients, 48
for pneumonia in urban-dwelling HIV-infected women, 223
Ritonavir
with lopinavir, efficacy and treatment-limiting toxicity of with third protease inhibitor in treatment-experienced patients, 494
low-dose, pharmacokinetics and efficacy of in patients with prior antiretroviral therapy (letter), 240
pharmacokinetics of saquinavir with, 375
RNA persistence, in semen, adherence to antiretroviral therapy and, 435
RNA testing, for HIV diagnosis of infants, 192
ROC curve analysis, of lipodystrophy syndrome, 104
RT activity, morphine in modulation of with in vitro coinfection, 406
Rural populations, age differences in sexual partners and HIV-1 risk in, 446

Safe injection facilities, impact of on public health and community, 2
Safety
of atazanavir with didanosine and stavudine, 18
of prednisone with CD4 cell counts of 200–700 mm, 281
Salvage therapy, real versus virtual phenotype guiding, 268
Santos, Brazil, incident HIV infection, 551
Saquinavir
pharmacokinetics and efficacy of in patients with prior antiretroviral therapy (letter), 240
pharmacokinetics of hard and soft capsules of with ritonavir, 375
SDF-1 allele frequencies, in Chinese populations, 124
Self-reported symptoms, after highly active antiretroviral therapy, 38
Semen
HIV-1 RNA levels in with resistance to lopinavir (letter), 462
HIV RNA persistence in and adherence to antiretroviral therapy, 435
Sensitive/less-sensitive test strategy, in HIV-1 infection classification, 94
Sentinel serosurveillance
in Canada, S24
in Germany, S49
global perspective on, S3
implementation of, S1
in Japan, S55
in Thailand, S63
Seroconversion
avidity index and automated enzyme immunoassay in identifying, 424
short-term CD4 cell response after HAART with, 303
Serologic techniques, for HIV-1 infection classification, 94
Serostatus Approach to Fighting HIV (SAFE), CDC, 196
Serosurveillance, S1
in Australia, S18
in Germany, S49
in Japan, S55
in Thailand, S63
in United States, S68
Sexual behavior
in gay bathhouses, public policy regulating, 417
HIV knowledge and among men who have sex with men in Vietnam, 80
in HIV transmission in Japan, S55
and HIV treatments optimism among gay men, 545
Sexual partners, age difference in and HIV-1 infection risk in rural Uganda, 446
Sexual transmission
of HIV in Tanzania (letter), 349, 351
of human T-cell lymphotropic virus type I, 328
Sexually transmitted disease clinics
HIV testing in, S1
versus mobile health van, 388
new strategies among clients of, 318
Sexually transmitted disease (STDs)
knowledge of among men who have sex with men in Vietnam, 80
risk of HIV transmission with, S39
treated by mobile health vans versus traditional STD clinics, 388
SF-36 assessment, after highly active antiretroviral therapy, 38
Shooting galleries, social circumstances of injection drug use in, 86
Simian immunodeficiency virus (SIV), from multiple lineages infecting human macrophages, 362
Social networks, of injection drug users in shooting galleries, 86
Sociodemographic factors, in voluntary HIV testing among inmates, 534
Socioeconomic factors, in risk of pneumonia among urban-dwelling HIV-infected women, 223
Sooty mangabeys, zoonotic cross-species transmission of SIVs from, 362
Southeast Asia
assessing magnitude of HIV/AIDS epidemic in, 311
HIV/AIDS surveillance in, S63
survival benefit from non-highly active antiretroviral therapy in, 157
Stavudine, with atazanavir, phase 2 clinical trial with, 18

Substance abuse, impaired virologic response to highly active antiretroviral therapy with, 522
Surveillance
of HIV/AIDS epidemic in Burma, 311
in identifying recent HIV infections, 424
Surveillance systems
in Australia, S18
behavioral data in, S12
in Canada, S24
future of, S68
global perspective on, S3
themes in, S1
Survival
C-reactive protein as predictor of in HIV-1-infected women, 210
effects of cessation of zidovudine prophylaxis on pregnant women, 170
non-highly active antiretroviral therapy and, 157

T cells
env-specific responses of, 9
prednisone effects on activation of, 281
T-helper responses, env-specific, 9
Tanzania
sexual transmission of HIV in (letter), 349, 351
weight gain in pregnant women with HIV-1 from, 560
Tertiary care center, HIV-2 sub-epidemic in (letter), 573
Thailand
HIV/AIDS surveillance in, S63
sentinel surveillance in, S1
survival benefit from non-highly active antiretroviral therapy in, 157
Therapy guidelines, markers and cofactors in, 514
Transduction, of macaque primary CD4-enriched peripheral blood mononuclear cell, 245
Transmission, phosphorylation of 3′-azidothymidine in maternal and fetal PBMCs and, 477
Treatment
HCV genotypes and failure of in HIV-positive drug users (letter), 465
optimism about among gay men, 545
Tropical spastic paraparesis, cluster of HTLV-I-associated myelopathy and in Argentina, 441

Uganda, age differences in sexual partners and HIV-1 risk in, 446
United States, HIV/AIDS surveillance in, S68
Urban clinics, factors associated with highly active antiretroviral therapy use in new patients in, 399
Urban population, risk factors for pneumonia among, 223
Urinalysis, in monitoring indinavir treatment effects, 135

Vaccine trials
efficacy, prototype informed consent process for, 161
informed consent in (editorial), 117
Venezuela, molecular epidemiology of HIV-1 in, 338
Vertical transmission
long-term outcomes in (editorial), 353
zidovudine prophylaxis to prevent, effect of cessation of, 170
Vietnam, HIV knowledge and risk factors among men who have sex with men in, 80
Viral load
antiretroviral drug plasma concentrations and in children (letter), 112
and gender in response to highly active antiretroviral therapy, 452
in HIV diagnosis of infants, 192
in semen, adherence to antiretroviral therapy and, 435
undetectable, on protease inhibitor- versus non-protease inhibitor-based highly active antiretroviral therapy (letter), 570
Viral shedding, adherence to antiretroviral therapy and, 435
Virologic failure, with lopinavir/ritonavir with third protease inhibitor, 494
Virologic response, impaired, with ongoing injection drug use, 522
Virology
in AIDS-related lymphoma (letter), 347
gender and in response to highly active antiretroviral therapy, 452
of prednisone with CD4 cell counts of 200–700 mm, 281
Visceral leishmaniasis, HIV coinfection with in India (letter), 572
Voluntary HIV counseling and testing settings, strategies for administering nevirapine to prevent perinatal HIV transmission in, 506

Waist circumference, increased intra-media thickness and, 490
Weight, patterns among pregnant HIV-1-infected women, 560
Women
C-reactive protein as mortality predictor in, 210
effects of cessation of zidovudine prophylaxis on, 170
HIV-infected, uninfected children born to, 380
long-term outcomes of infants born to (editorial), 353
nevirapine administration strategies to prevent perinatal HIV transmission by, 506
placenta and cord blood mitochondrial DNA toxicity in, 370
protease inhibitor use and diabetes mellitus in, 298
proteinuria and elevated serum creatinine levels in mortality among, 203
risk factors for pneumonia among, 223
use of highly active antiretroviral therapy among, 399

Zidovudine
effects of cessation of prophylactic use of on maternal HIV disease, 170
health of uninfected children exposed to in utero or early life, 380
Zoonotic cross-species transmission, of SIVs, 362